Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Fevipiprant
Cat. No.:
0225LY-1125
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Fevipiprant acts as a potent, selective, and reversible competitive antagonist of the CRTh2 receptor.
Synonym:
QAW039; NVP-QAW039; 872365-14-5; 2-(2-methyl-1-(4-(methylsulfonyl)-2-(trifluoromethyl)benzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid; 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl]methyl]pyrrolo[2,3-b]pyridin-3-yl]acetic acid; (1-(4-((Methane)sulfonyl)-2-trifluoromethylbenzyl)-2-methyl-1H-pyrrolo(2,3-b)pyridin-3-yl)acetic acid; 2-(1-((4-Methanesulfonyl-2-(trifluoromethyl)phenyl)methyl(-2-methyl-1H-pyrrolo(2,3-b)pyridin-3-yl)acetic acid
CAS No.:
872365-14-5
Compound CID:
23582412
Formula:
C19H17F3N2O4S
Formula Weight:
426.41
Specification
Targets&IC50:
CRTH2: 0.44 nM
Relative Density:
1.44 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Fevipiprant can be used in asthma research to examine the selective antagonism of the DP2 (CRTH2) receptor.
Library Information
Target:
Prostaglandin receptor; GPR
Receptor:
CRTh2; Prostaglandin receptor
Pathways:
Immunology/Inflammation; GPCR/G protein signaling; Endocrinology/Hormones
Plate Number:
AOCL-15
Plate Location:
d11
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
60 mg/mL; 140.71 mM
